About The Study: Among patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction treated with dapagliflozin in this randomized clinical trial, an initial estimated glomerular filtration rate (eGFR) decline was frequent but not associated with subsequent risk of cardiovascular or kidney events. These data reinforce clinical guidance that sodium-glucose cotransporter-2 inhibitors should not be interrupted or discontinued in response to an initial eGFR decline.
Authors: Finnian R. Mc Causland, M.B.B.Ch., M.M.Sc., of Brigham and Women’s Hospital in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2023.4664)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the American Heart Association’s Scientific Sessions 2023.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2023.4664?guestAccessKey=a781b965-6d63-46b9-9d1b-5eb7e7a6e4e6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111223
JAMA Cardiology